MersV1, Istex, Corpus, bibRecord, 001392

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients

Identifieur interne : 001392 ( Istex/Corpus ); précédent : 001391; suivant : 001393

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients

Auteurs : Yonghong Zhang ; Yali Liu ; Yan Zhao ; Lingxian Shi ; Lina Ma ; Huiping Yan ; Hao Wu ; Lai Wei ; Tao Dong ; Xinyue Chen

Source :

Liver International [ 1478-3223 ] ; 2012-01.

RBID : ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D

English descriptors

Teeft :
- Acute hepatitis, Antiviral therapy, Assay, Baseline, Beijing, Beijing youan hospital, Cell responses, Certain patients, Chronic hepatitis, Chronic infection, Chronic patients, Clin virol, Combination therapy, Combination treatment, Control wells, Demographic characteristics, Early virological response, Elispot, Elispot assay, Genetic variation, Genotype, Hepatitis, Interferon, John wiley sons, John wiley sons response, John wiley sons zhang, Nonstructural, Nonstructural protein, Ns5a, Pbmcs, Peptide, Peptide pools, Peripheral blood, Rapid virological response, Responsive patients, Ribavirin, Study group, Suppressive effect, Therapy, Undetectable serum, Viral, Viral clearance, Viral kinetics, Viral load, Virological, Virological response, Virus clearance, Virus infection, Virus nonstructural protein, Zhang.

Abstract

Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.

Url:

https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.pdf

DOI: 10.1111/j.1478-3231.2011.02652.x

Links to Exploration step

ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
<author><name sortKey="Zhang, Yonghong" sort="Zhang, Yonghong" uniqKey="Zhang Y" first="Yonghong" last="Zhang">Yonghong Zhang</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Yali" sort="Liu, Yali" uniqKey="Liu Y" first="Yali" last="Liu">Yali Liu</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shi, Lingxian" sort="Shi, Lingxian" uniqKey="Shi L" first="Lingxian" last="Shi">Lingxian Shi</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Lina" sort="Ma, Lina" uniqKey="Ma L" first="Lina" last="Ma">Lina Ma</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wei, Lai" sort="Wei, Lai" uniqKey="Wei L" first="Lai" last="Wei">Lai Wei</name>
<affiliation><mods:affiliation>Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dong, Tao" sort="Dong, Tao" uniqKey="Dong T" first="Tao" last="Dong">Tao Dong</name>
<affiliation><mods:affiliation>MRC Human Immunolgy Unit, WIMM, University of Oxford, Oxford, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Professor Xinyue Chen, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, ChinaTel: 0086 10 63050639Fax: 0086 10 63054847e‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: chenxy63050639@yahoo.com.cn</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1111/j.1478-3231.2011.02652.x</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001392</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001392</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
<author><name sortKey="Zhang, Yonghong" sort="Zhang, Yonghong" uniqKey="Zhang Y" first="Yonghong" last="Zhang">Yonghong Zhang</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Liu, Yali" sort="Liu, Yali" uniqKey="Liu Y" first="Yali" last="Liu">Yali Liu</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhao, Yan" sort="Zhao, Yan" uniqKey="Zhao Y" first="Yan" last="Zhao">Yan Zhao</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Shi, Lingxian" sort="Shi, Lingxian" uniqKey="Shi L" first="Lingxian" last="Shi">Lingxian Shi</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Ma, Lina" sort="Ma, Lina" uniqKey="Ma L" first="Lina" last="Ma">Lina Ma</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Yan, Huiping" sort="Yan, Huiping" uniqKey="Yan H" first="Huiping" last="Yan">Huiping Yan</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wu, Hao" sort="Wu, Hao" uniqKey="Wu H" first="Hao" last="Wu">Hao Wu</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Wei, Lai" sort="Wei, Lai" uniqKey="Wei L" first="Lai" last="Wei">Lai Wei</name>
<affiliation><mods:affiliation>Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Dong, Tao" sort="Dong, Tao" uniqKey="Dong T" first="Tao" last="Dong">Tao Dong</name>
<affiliation><mods:affiliation>MRC Human Immunolgy Unit, WIMM, University of Oxford, Oxford, UK</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Chen, Xinyue" sort="Chen, Xinyue" uniqKey="Chen X" first="Xinyue" last="Chen">Xinyue Chen</name>
<affiliation><mods:affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>Professor Xinyue Chen, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, ChinaTel: 0086 10 63050639Fax: 0086 10 63054847e‐mail:</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>E-mail: chenxy63050639@yahoo.com.cn</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Liver International</title>
<title level="j" type="alt">LIVER INTERNATIONAL</title>
<idno type="ISSN">1478-3223</idno>
<idno type="eISSN">1478-3231</idno>
<imprint><biblScope unit="vol">32</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="102">102</biblScope>
<biblScope unit="page" to="109">109</biblScope>
<biblScope unit="page-count">8</biblScope>
<date type="published" when="2012-01">2012-01</date>
</imprint>
<idno type="ISSN">1478-3223</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1478-3223</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute hepatitis</term>
<term>Antiviral therapy</term>
<term>Assay</term>
<term>Baseline</term>
<term>Beijing</term>
<term>Beijing youan hospital</term>
<term>Cell responses</term>
<term>Certain patients</term>
<term>Chronic hepatitis</term>
<term>Chronic infection</term>
<term>Chronic patients</term>
<term>Clin virol</term>
<term>Combination therapy</term>
<term>Combination treatment</term>
<term>Control wells</term>
<term>Demographic characteristics</term>
<term>Early virological response</term>
<term>Elispot</term>
<term>Elispot assay</term>
<term>Genetic variation</term>
<term>Genotype</term>
<term>Hepatitis</term>
<term>Interferon</term>
<term>John wiley sons</term>
<term>John wiley sons response</term>
<term>John wiley sons zhang</term>
<term>Nonstructural</term>
<term>Nonstructural protein</term>
<term>Ns5a</term>
<term>Pbmcs</term>
<term>Peptide</term>
<term>Peptide pools</term>
<term>Peripheral blood</term>
<term>Rapid virological response</term>
<term>Responsive patients</term>
<term>Ribavirin</term>
<term>Study group</term>
<term>Suppressive effect</term>
<term>Therapy</term>
<term>Undetectable serum</term>
<term>Viral</term>
<term>Viral clearance</term>
<term>Viral kinetics</term>
<term>Viral load</term>
<term>Virological</term>
<term>Virological response</term>
<term>Virus clearance</term>
<term>Virus infection</term>
<term>Virus nonstructural protein</term>
<term>Zhang</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</div>
</front>
</TEI>
<istex><corpusName>wiley</corpusName>
<keywords><teeft><json:string>combination therapy</json:string>
<json:string>virological</json:string>
<json:string>viral</json:string>
<json:string>ribavirin</json:string>
<json:string>virological response</json:string>
<json:string>pbmcs</json:string>
<json:string>ns5a</json:string>
<json:string>elispot</json:string>
<json:string>nonstructural</json:string>
<json:string>interferon</json:string>
<json:string>viral clearance</json:string>
<json:string>beijing</json:string>
<json:string>genotype</json:string>
<json:string>peptide</json:string>
<json:string>chronic hepatitis</json:string>
<json:string>hepatitis</json:string>
<json:string>zhang</json:string>
<json:string>virus infection</json:string>
<json:string>responsive patients</json:string>
<json:string>assay</json:string>
<json:string>john wiley sons zhang</json:string>
<json:string>nonstructural protein</json:string>
<json:string>baseline</json:string>
<json:string>antiviral therapy</json:string>
<json:string>beijing youan hospital</json:string>
<json:string>acute hepatitis</json:string>
<json:string>virus nonstructural protein</json:string>
<json:string>therapy</json:string>
<json:string>early virological response</json:string>
<json:string>chronic infection</json:string>
<json:string>chronic patients</json:string>
<json:string>demographic characteristics</json:string>
<json:string>peripheral blood</json:string>
<json:string>rapid virological response</json:string>
<json:string>john wiley sons response</json:string>
<json:string>undetectable serum</json:string>
<json:string>study group</json:string>
<json:string>certain patients</json:string>
<json:string>peptide pools</json:string>
<json:string>control wells</json:string>
<json:string>elispot assay</json:string>
<json:string>john wiley sons</json:string>
<json:string>combination treatment</json:string>
<json:string>suppressive effect</json:string>
<json:string>virus clearance</json:string>
<json:string>viral load</json:string>
<json:string>clin virol</json:string>
<json:string>cell responses</json:string>
<json:string>genetic variation</json:string>
<json:string>viral kinetics</json:string>
</teeft>
</keywords>
<author><json:item><name>Yonghong Zhang</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Yali Liu</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Yan Zhao</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Lingxian Shi</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Lina Ma</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Huiping Yan</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Hao Wu</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Lai Wei</name>
<affiliations><json:string>Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China</json:string>
</affiliations>
</json:item>
<json:item><name>Tao Dong</name>
<affiliations><json:string>MRC Human Immunolgy Unit, WIMM, University of Oxford, Oxford, UK</json:string>
</affiliations>
</json:item>
<json:item><name>Xinyue Chen</name>
<affiliations><json:string>Beijing You'an Hospital, Capital Medical University,, Beijing, China</json:string>
<json:string>Professor Xinyue Chen, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, ChinaTel: 0086 10 63050639Fax: 0086 10 63054847e‐mail:</json:string>
<json:string>E-mail: chenxy63050639@yahoo.com.cn</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>combination therapy</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>hepatitis C virus (HCV)</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>nonstructural protein (NS)</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>sustained virological response</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>T cell</value>
</json:item>
</subject>
<articleId><json:string>LIV2652</json:string>
</articleId>
<arkIstex>ark:/67375/WNG-JJ0J5KLG-M</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>article</json:string>
</originalGenre>
<abstract>Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</abstract>
<qualityIndicators><score>8.526</score>
<pdfWordCount>4102</pdfWordCount>
<pdfCharCount>28615</pdfCharCount>
<pdfVersion>1.3</pdfVersion>
<pdfPageCount>8</pdfPageCount>
<pdfPageSize>595.276 x 782.362 pts</pdfPageSize>
<pdfWordsPerPage>513</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>202</abstractWordCount>
<abstractCharCount>1496</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
<pmid><json:string>22098382</json:string>
</pmid>
<genre><json:string>article</json:string>
</genre>
<host><title>Liver International</title>
<language><json:string>unknown</json:string>
</language>
<doi><json:string>10.1111/(ISSN)1478-3231</json:string>
</doi>
<issn><json:string>1478-3223</json:string>
</issn>
<eissn><json:string>1478-3231</json:string>
</eissn>
<publisherId><json:string>LIV</json:string>
</publisherId>
<volume>32</volume>
<issue>1</issue>
<pages><first>102</first>
<last>109</last>
<total>8</total>
</pages>
<genre><json:string>journal</json:string>
</genre>
<subject><json:item><value>Clinical Studies</value>
</json:item>
<json:item><value>Clinical Studies</value>
</json:item>
</subject>
</host>
<namedEntities><unitex><date><json:string>2011-09-09</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Virahep‐C Study Group</json:string>
<json:string>University of Oxford</json:string>
<json:string>Roche Molecular Systems</json:string>
<json:string>American Association for the Study of Liver Diseases</json:string>
<json:string>Hospital, Capital Medical University, Beijing, China</json:string>
<json:string>Beijing Youan Hospital, Capital Medical University</json:string>
<json:string>China Tel</json:string>
<json:string>BD Immunocytochemistry Systems, San</json:string>
<json:string>Peking University Hepatology Institute, Peking University People</json:string>
<json:string>Mabtech, Stockholm, Sweden</json:string>
<json:string>Elispot Collaborative Study Group</json:string>
<json:string>SigmaAldrich Co</json:string>
<json:string>UK Keywords</json:string>
<json:string>China and India</json:string>
<json:string>HCV Liver International</json:string>
<json:string>Mabtech</json:string>
<json:string>Liver International</json:string>
</orgName>
<orgName_funder></orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Lina Ma</json:string>
<json:string>Lai Wei</json:string>
<json:string>John Wiley</json:string>
<json:string>Yan Zhao</json:string>
<json:string>Project</json:string>
<json:string>Tao Dong</json:string>
<json:string>To</json:string>
<json:string>Hao Wu</json:string>
</persName>
<placeName><json:string>Germany</json:string>
<json:string>Beijing</json:string>
<json:string>UK</json:string>
<json:string>Norway</json:string>
<json:string>Oslo</json:string>
<json:string>China</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>Zhang et al.</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/WNG-JJ0J5KLG-M</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - gastroenterology & hepatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - gastroenterology & hepatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Hepatology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>2012</publicationDate>
<copyrightDate>2012</copyrightDate>
<doi><json:string>10.1111/j.1478-3231.2011.02652.x</json:string>
</doi>
<id>1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher>
<availability><licence>© 2011 John Wiley & Sons A/S</licence>
</availability>
<date type="published" when="2012-01"></date>
</publicationStmt>
<notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
<author xml:id="author-0000"><persName><forename type="first">Yonghong</forename>
<surname>Zhang</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">Yali</forename>
<surname>Liu</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">Yan</forename>
<surname>Zhao</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">Lingxian</forename>
<surname>Shi</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">Lina</forename>
<surname>Ma</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><forename type="first">Huiping</forename>
<surname>Yan</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0006"><persName><forename type="first">Hao</forename>
<surname>Wu</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0007"><persName><forename type="first">Lai</forename>
<surname>Wei</surname>
</persName>
<affiliation><orgName type="division">Peking University Hepatology Institute</orgName>
<orgName type="institution">Peking University People's Hospital</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<author xml:id="author-0008"><persName><forename type="first">Tao</forename>
<surname>Dong</surname>
</persName>
<affiliation><orgName type="division">MRC Human Immunolgy Unit</orgName>
<orgName type="division">WIMM</orgName>
<orgName type="institution">University of Oxford</orgName>
<address><settlement>Oxford</settlement>
<country key="GB" xml:lang="en">UNITED KINGDOM</country>
</address>
</affiliation>
</author>
<author xml:id="author-0009" role="corresp"><persName><forename type="first">Xinyue</forename>
<surname>Chen</surname>
</persName>
<affiliation><orgName type="division">Beijing You'an Hospital</orgName>
<orgName type="institution">Capital Medical University,</orgName>
<address><settlement>Beijing</settlement>
<country key="CN" xml:lang="en">CHINA</country>
</address>
</affiliation>
</author>
<idno type="istex">1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D</idno>
<idno type="ark">ark:/67375/WNG-JJ0J5KLG-M</idno>
<idno type="DOI">10.1111/j.1478-3231.2011.02652.x</idno>
<idno type="unit">LIV2652</idno>
<idno type="toTypesetVersion">file:LIV.LIV2652.pdf</idno>
</analytic>
<monogr><title level="j" type="main">Liver International</title>
<title level="j" type="alt">LIVER INTERNATIONAL</title>
<idno type="pISSN">1478-3223</idno>
<idno type="eISSN">1478-3231</idno>
<idno type="book-DOI">10.1111/(ISSN)1478-3231</idno>
<idno type="book-part-DOI">10.1111/liv.2011.32.issue-1</idno>
<idno type="product">LIV</idno>
<imprint><biblScope unit="vol">32</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="102">102</biblScope>
<biblScope unit="page" to="109">109</biblScope>
<biblScope unit="page-count">8</biblScope>
<date type="published" when="2012-01"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract style="main" xml:id="liv2652-abs-0001"><head>Abstract</head>
<head>Background</head>
<p>Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (<hi rend="fc">HCV</hi>
)‐specific T‐cell responses on combination therapy still remains controversial.</p>
<head>Aims</head>
<p>To identify the association between <hi rend="fc">HCV</hi>
‐specific T cell responses and efficiency of combination therapy.</p>
<head>Methods</head>
<p>To address this issue, a longitudinal analysis of <hi rend="fc">HCV</hi>
‐specific T‐cell responses to overlapping peptides covering <hi rend="fc">HCV</hi>
‐nonstructural protein (<hi rend="fc">NS</hi>
) was performed using <hi rend="fc">ELIS</hi>
pot assay in 48 chronically infected <hi rend="fc">HCV</hi>
‐1b patients during combination treatment with peginterferon‐alfa and ribavirin.</p>
<head>Results</head>
<p>Fifty‐two percent of chronic <hi rend="fc">HCV</hi>
 patients showed detectable <hi rend="fc">HCV</hi>
‐<hi rend="fc">NS</hi>
3, <hi rend="fc">NS</hi>
4 or <hi rend="fc">NS</hi>
5A specific T‐cell responses before therapy, with <hi rend="fc">NS</hi>
3 appearing to be the most immunodominant protein followed by <hi rend="fc">NS</hi>
5A and <hi rend="fc">NS</hi>
4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (<hi rend="fc">SVR</hi>
) when compared with those without <hi rend="fc">SVR</hi>
. Dynamics of <hi rend="fc">HCV</hi>
‐<hi rend="fc">NS</hi>
‐specific T‐cell responses were further analysed; we found that <hi rend="fc">HCV</hi>
‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with <hi rend="fc">SVR</hi>
. In contrast, <hi rend="fc">HCV</hi>
‐specific T‐cell responses in patients without <hi rend="fc">SVR</hi>
 declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks.</p>
<head>Conclusion</head>
<p>We found that the <hi rend="fc">HCV</hi>
‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</p>
</abstract>
<textClass><keywords><term xml:id="liv2652-kwd-0001">combination therapy</term>
<term xml:id="liv2652-kwd-0002">hepatitis C virus (<hi rend="fc">HCV</hi>
)</term>
<term xml:id="liv2652-kwd-0003">nonstructural protein (<hi rend="fc">NS</hi>
)</term>
<term xml:id="liv2652-kwd-0004">sustained virological response</term>
<term xml:id="liv2652-kwd-0005">T cell</term>
</keywords>
<keywords rend="articleCategory"><term>Clinical Studies</term>
</keywords>
<keywords rend="tocHeading1"><term>Clinical Studies</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document><component type="serialArticle" version="2.0" xml:id="liv2652" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1478-3231</doi>
<issn type="print">1478-3223</issn>
<issn type="electronic">1478-3231</issn>
<idGroup><id type="product" value="LIV"></id>
</idGroup>
<titleGroup><title sort="LIVER INTERNATIONAL" type="main">Liver International</title>
<title type="short">Liver Int.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="01101"><doi origin="wiley">10.1111/liv.2011.32.issue-1</doi>
<copyright ownership="publisher">© 2012 John Wiley & Sons A/S</copyright>
<numberingGroup><numbering number="32" type="journalVolume">32</numbering>
<numbering type="journalIssue">1</numbering>
</numberingGroup>
<coverDate startDate="2012-01">January 2012</coverDate>
</publicationMeta>
<publicationMeta level="unit" position="15" status="forIssue" type="article"><doi>10.1111/j.1478-3231.2011.02652.x</doi>
<idGroup><id type="unit" value="LIV2652"></id>
</idGroup>
<countGroup><count number="8" type="pageTotal"></count>
</countGroup>
<titleGroup><title type="articleCategory">Clinical Studies</title>
<title type="tocHeading1">Clinical Studies</title>
</titleGroup>
<copyright ownership="publisher">© 2011 John Wiley & Sons A/S</copyright>
<eventGroup><event date="2011-02-13" type="manuscriptReceived"></event>
<event date="2011-08-26" type="manuscriptAccepted"></event>
<event agent="SPS" date="2011-09-09" type="xmlCreated"></event>
<event type="publishedOnlineEarlyUnpaginated" date="2011-09-26"></event>
<event type="firstOnline" date="2011-09-26"></event>
<event type="publishedOnlineFinalForm" date="2011-12-07"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-01"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.4 mode:FullText" date="2015-02-25"></event>
</eventGroup>
<numberingGroup><numbering type="pageFirst">102</numbering>
<numbering type="pageLast">109</numbering>
</numberingGroup>
<correspondenceTo><lineatedText><line><b>Correspondence</b>
</line>
<line>Professor Xinyue Chen, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, China</line>
<line>Tel: 0086 10 63050639</line>
<line>Fax: 0086 10 63054847</line>
<line>e‐mail: <email>chenxy63050639@yahoo.com.cn</email>
</line>
</lineatedText>
</correspondenceTo>
<linkGroup><link type="toTypesetVersion" href="file:LIV.LIV2652.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta><titleGroup><title type="main">Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic <fc>HCV</fc>
 patients</title>
<title type="shortAuthors">Zhang <i>et al</i>
.</title>
</titleGroup>
<creators><creator affiliationRef="#liv2652-aff-0001" creatorRole="author" noteRef="#liv2652-note-0001" xml:id="liv2652-cr-0001"><personName><givenNames>Yonghong</givenNames>
<familyName>Zhang</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" noteRef="#liv2652-note-0001" xml:id="liv2652-cr-0002"><personName><givenNames>Yali</givenNames>
<familyName>Liu</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" noteRef="#liv2652-note-0001" xml:id="liv2652-cr-0003"><personName><givenNames>Yan</givenNames>
<familyName>Zhao</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" xml:id="liv2652-cr-0004"><personName><givenNames>Lingxian</givenNames>
<familyName>Shi</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" xml:id="liv2652-cr-0005"><personName><givenNames>Lina</givenNames>
<familyName>Ma</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" xml:id="liv2652-cr-0006"><personName><givenNames>Huiping</givenNames>
<familyName>Yan</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" creatorRole="author" xml:id="liv2652-cr-0007"><personName><givenNames>Hao</givenNames>
<familyName>Wu</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0002" creatorRole="author" xml:id="liv2652-cr-0008"><personName><givenNames>Lai</givenNames>
<familyName>Wei</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0003" creatorRole="author" noteRef="#liv2652-note-0001" xml:id="liv2652-cr-0009"><personName><givenNames>Tao</givenNames>
<familyName>Dong</familyName>
</personName>
</creator>
<creator affiliationRef="#liv2652-aff-0001" corresponding="yes" creatorRole="author" noteRef="#liv2652-note-0001" xml:id="liv2652-cr-0010"><personName><givenNames>Xinyue</givenNames>
<familyName>Chen</familyName>
</personName>
</creator>
</creators>
<affiliationGroup><affiliation countryCode="CN" type="organization" xml:id="liv2652-aff-0001"><orgDiv>Beijing You'an Hospital</orgDiv>
<orgName>Capital Medical University,</orgName>
<address><city>Beijing</city>
<country>China</country>
</address>
</affiliation>
<affiliation countryCode="CN" type="organization" xml:id="liv2652-aff-0002"><orgDiv>Peking University Hepatology Institute</orgDiv>
<orgName>Peking University People's Hospital</orgName>
<address><city>Beijing</city>
<country>China</country>
</address>
</affiliation>
<affiliation countryCode="GB" type="organization" xml:id="liv2652-aff-0003"><orgDiv>MRC Human Immunolgy Unit</orgDiv>
<orgDiv>WIMM</orgDiv>
<orgName>University of Oxford</orgName>
<address><city>Oxford</city>
<country>UK</country>
</address>
</affiliation>
</affiliationGroup>
<keywordGroup type="author"><keyword xml:id="liv2652-kwd-0001">combination therapy</keyword>
<keyword xml:id="liv2652-kwd-0002">hepatitis C virus (<fc>HCV</fc>
)</keyword>
<keyword xml:id="liv2652-kwd-0003">nonstructural protein (<fc>NS</fc>
)</keyword>
<keyword xml:id="liv2652-kwd-0004">sustained virological response</keyword>
<keyword xml:id="liv2652-kwd-0005">T cell</keyword>
</keywordGroup>
<fundingInfo><fundingAgency>Beijing Municipal Health Bureau</fundingAgency>
<fundingNumber>QN2009‐29</fundingNumber>
</fundingInfo>
<fundingInfo><fundingAgency>Beijing Municipal Science & Technology Commission</fundingAgency>
<fundingNumber>D09050703560902</fundingNumber>
</fundingInfo>
<fundingInfo><fundingAgency>National S&T Major Project for Infectious Diseases Control</fundingAgency>
<fundingNumber>2008ZX10002‐013</fundingNumber>
</fundingInfo>
<abstractGroup><abstract type="main" xml:id="liv2652-abs-0001"><title type="main">Abstract</title>
<section xml:id="liv2652-sec-0001"><title type="main">Background</title>
<p>Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (<fc>HCV</fc>
)‐specific T‐cell responses on combination therapy still remains controversial.</p>
</section>
<section xml:id="liv2652-sec-0002"><title type="main">Aims</title>
<p>To identify the association between <fc>HCV</fc>
‐specific T cell responses and efficiency of combination therapy.</p>
</section>
<section xml:id="liv2652-sec-0003"><title type="main">Methods</title>
<p>To address this issue, a longitudinal analysis of <fc>HCV</fc>
‐specific T‐cell responses to overlapping peptides covering <fc>HCV</fc>
‐nonstructural protein (<fc>NS</fc>
) was performed using <fc>ELIS</fc>
pot assay in 48 chronically infected <fc>HCV</fc>
‐1b patients during combination treatment with peginterferon‐alfa and ribavirin.</p>
</section>
<section xml:id="liv2652-sec-0004"><title type="main">Results</title>
<p>Fifty‐two percent of chronic <fc>HCV</fc>
 patients showed detectable <fc>HCV</fc>
‐<fc>NS</fc>
3, <fc>NS</fc>
4 or <fc>NS</fc>
5A specific T‐cell responses before therapy, with <fc>NS</fc>
3 appearing to be the most immunodominant protein followed by <fc>NS</fc>
5A and <fc>NS</fc>
4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (<fc>SVR</fc>
) when compared with those without <fc>SVR</fc>
. Dynamics of <fc>HCV</fc>
‐<fc>NS</fc>
‐specific T‐cell responses were further analysed; we found that <fc>HCV</fc>
‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with <fc>SVR</fc>
. In contrast, <fc>HCV</fc>
‐specific T‐cell responses in patients without <fc>SVR</fc>
 declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks.</p>
</section>
<section xml:id="liv2652-sec-0005"><title type="main">Conclusion</title>
<p>We found that the <fc>HCV</fc>
‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</p>
</section>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup xml:id="liv2652-ntgp-0001"><note xml:id="liv2652-note-0001">These authors contributed equally to this paper.</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en"><title>Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients</title>
</titleInfo>
<name type="personal"><namePart type="given">Yonghong</namePart>
<namePart type="family">Zhang</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<description>These authors contributed equally to this paper.</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Yali</namePart>
<namePart type="family">Liu</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<description>These authors contributed equally to this paper.</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Yan</namePart>
<namePart type="family">Zhao</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<description>These authors contributed equally to this paper.</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Lingxian</namePart>
<namePart type="family">Shi</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Lina</namePart>
<namePart type="family">Ma</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Huiping</namePart>
<namePart type="family">Yan</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Hao</namePart>
<namePart type="family">Wu</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Lai</namePart>
<namePart type="family">Wei</namePart>
<affiliation>Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Tao</namePart>
<namePart type="family">Dong</namePart>
<affiliation>MRC Human Immunolgy Unit, WIMM, University of Oxford, Oxford, UK</affiliation>
<description>These authors contributed equally to this paper.</description>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Xinyue</namePart>
<namePart type="family">Chen</namePart>
<affiliation>Beijing You'an Hospital, Capital Medical University,, Beijing, China</affiliation>
<description>These authors contributed equally to this paper.</description>
<affiliation>Professor Xinyue Chen, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai Street, Fengtai District, Beijing, 100069, ChinaTel: 0086 10 63050639Fax: 0086 10 63054847e‐mail:</affiliation>
<affiliation>E-mail: chenxy63050639@yahoo.com.cn</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre>
<originInfo><publisher>Blackwell Publishing Ltd</publisher>
<dateIssued encoding="w3cdtf">2012-01</dateIssued>
<dateCreated encoding="w3cdtf">2011-09-09</dateCreated>
<dateCaptured encoding="w3cdtf">2011-02-13</dateCaptured>
<dateValid encoding="w3cdtf">2011-08-26</dateValid>
<copyrightDate encoding="w3cdtf">2012</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<abstract>Background: Virus‐specific T‐cell responses play a major role in antiviral immune response. However, the effect of hepatitis C virus (HCV)‐specific T‐cell responses on combination therapy still remains controversial. Aims: To identify the association between HCV‐specific T cell responses and efficiency of combination therapy. Methods: To address this issue, a longitudinal analysis of HCV‐specific T‐cell responses to overlapping peptides covering HCV‐nonstructural protein (NS) was performed using ELISpot assay in 48 chronically infected HCV‐1b patients during combination treatment with peginterferon‐alfa and ribavirin. Results: Fifty‐two percent of chronic HCV patients showed detectable HCV‐NS3, NS4 or NS5A specific T‐cell responses before therapy, with NS3 appearing to be the most immunodominant protein followed by NS5A and NS4. In addition, the percentage of patients responding to peptide stimulation was higher in patients with sustained virological response (SVR) when compared with those without SVR. Dynamics of HCV‐NS‐specific T‐cell responses were further analysed; we found that HCV‐specific T‐cell responses maintained higher levels at 12 weeks into treatment in patients with SVR. In contrast, HCV‐specific T‐cell responses in patients without SVR declined significantly at 4 weeks into treatment and maintained low levels at 12 weeks. Conclusion: We found that the HCV‐specific T‐cell responses were associated with good viral control in patients with combination therapy.</abstract>
<note type="funding">Beijing Municipal Health Bureau - No. QN2009‐29; </note>
<note type="funding">Beijing Municipal Science & Technology Commission - No. D09050703560902; </note>
<note type="funding">National S&T Major Project for Infectious Diseases Control - No. 2008ZX10002‐013; </note>
<subject><genre>keywords</genre>
<topic>combination therapy</topic>
<topic>hepatitis C virus (HCV)</topic>
<topic>nonstructural protein (NS)</topic>
<topic>sustained virological response</topic>
<topic>T cell</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Liver International</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Liver Int.</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<subject><genre>article-category</genre>
<topic>Clinical Studies</topic>
<topic>Clinical Studies</topic>
</subject>
<identifier type="ISSN">1478-3223</identifier>
<identifier type="eISSN">1478-3231</identifier>
<identifier type="DOI">10.1111/(ISSN)1478-3231</identifier>
<identifier type="PublisherID">LIV</identifier>
<part><date>2012</date>
<detail type="volume"><caption>vol.</caption>
<number>32</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>102</start>
<end>109</end>
<total>8</total>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0001"><titleInfo><title>T cell response in hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Neumann‐Haefelin</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">HE</namePart>
<namePart type="family">Blum</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">FV</namePart>
<namePart type="family">Chisari</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Thimme</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Neumann‐HaefelinC, BlumHE, ChisariFV, ThimmeR. T cell response in hepatitis C virus infection. J Clin Virol2005; 32: 75–85.</note>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>32</number>
</detail>
<extent unit="pages"><start>75</start>
<end>85</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Virol</title>
</titleInfo>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>32</number>
</detail>
<extent unit="pages"><start>75</start>
<end>85</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0002"><titleInfo><title>Hepatitis C vaccine: supply and demand</title>
</titleInfo>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Inchauspé</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Honnet</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JY</namePart>
<namePart type="family">Bonnefoy</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Nicosia</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">GT</namePart>
<namePart type="family">Strickland</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">InchauspéG, HonnetG, BonnefoyJY, NicosiaA, StricklandGT. Hepatitis C vaccine: supply and demand. Lancet Infect Dis2008; 12: 739–40.</note>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>12</number>
</detail>
<extent unit="pages"><start>739</start>
<end>40</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Lancet Infect Dis</title>
</titleInfo>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>12</number>
</detail>
<extent unit="pages"><start>739</start>
<end>40</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0003"><titleInfo><title>Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</title>
</titleInfo>
<name type="personal"><namePart type="given">MP</namePart>
<namePart type="family">Manns</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JG</namePart>
<namePart type="family">McHutchison</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">SC</namePart>
<namePart type="family">Gordon</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">MannsMP, McHutchisonJG, GordonSC, et al. Peginterferon alpha‐2b plus ribavirin compared with interferon alpha‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–65.</note>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>358</number>
</detail>
<extent unit="pages"><start>958</start>
<end>65</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Lancet</title>
</titleInfo>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>358</number>
</detail>
<extent unit="pages"><start>958</start>
<end>65</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0004"><titleInfo><title>Peginterferon alpha‐2a plus ribavirin for chronic hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">MW</namePart>
<namePart type="family">Fried</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">ML</namePart>
<namePart type="family">Shiffman</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">KR</namePart>
<namePart type="family">Reddy</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">FriedMW, ShiffmanML, ReddyKR, et al. Peginterferon alpha‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–82.</note>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>347</number>
</detail>
<extent unit="pages"><start>975</start>
<end>82</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>N Engl J Med</title>
</titleInfo>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>347</number>
</detail>
<extent unit="pages"><start>975</start>
<end>82</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0005"><titleInfo><title>Peginterferon alpha‐ 2a (40 kD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose</title>
</titleInfo>
<name type="personal"><namePart type="given">SJ</namePart>
<namePart type="family">Hadziyannis</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">H</namePart>
<namePart type="family">Sette Jr</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">TR</namePart>
<namePart type="family">Morgan</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">HadziyannisSJ, SetteHJr, MorganTR, et al. Peginterferon alpha‐ 2a (40 kD) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med2004; 140: 346–55.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>140</number>
</detail>
<extent unit="pages"><start>346</start>
<end>55</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Ann Intern Med</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>140</number>
</detail>
<extent unit="pages"><start>346</start>
<end>55</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0006"><titleInfo><title>Hepatitis C virus infections and genotypes in China</title>
</titleInfo>
<name type="personal"><namePart type="given">YD</namePart>
<namePart type="family">Chen</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">MY</namePart>
<namePart type="family">Liu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">WL</namePart>
<namePart type="family">Yu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ChenYD, LiuMY, YuWL, et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int2002; 1: 194–201.</note>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>194</start>
<end>201</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Hepatobiliary Pancreat Dis Int</title>
</titleInfo>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>194</start>
<end>201</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0007"><titleInfo><title>HCV genotype 4–an emerging threat as a cause of chronic liver disease in Indian (south) patients</title>
</titleInfo>
<name type="personal"><namePart type="given">S</namePart>
<namePart type="family">Raghuraman</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P</namePart>
<namePart type="family">Abraham</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Sridharan</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">RaghuramanS, AbrahamP, SridharanG, et al. HCV genotype 4–an emerging threat as a cause of chronic liver disease in Indian (south) patients. J Clin Virol2004; 31: 253–8.</note>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>31</number>
</detail>
<extent unit="pages"><start>253</start>
<end>8</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Virol</title>
</titleInfo>
<part><date>2004</date>
<detail type="volume"><caption>vol.</caption>
<number>31</number>
</detail>
<extent unit="pages"><start>253</start>
<end>8</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0008"><titleInfo><title>Diagnosis, management, and treatment of hepatitis C: an update</title>
</titleInfo>
<name type="personal"><namePart type="given">MG</namePart>
<namePart type="family">Ghany</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">DB</namePart>
<namePart type="family">Strader</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">DL</namePart>
<namePart type="family">Thomas</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">LB</namePart>
<namePart type="family">Seeff</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="corporate"><namePart>American Association for the Study of Liver Diseases</namePart>
</name>
<genre>journal-article</genre>
<note type="citation/reference">GhanyMG, StraderDB, ThomasDL, SeeffLB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology2009; 49: 1335–74.</note>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>49</number>
</detail>
<extent unit="pages"><start>1335</start>
<end>74</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Hepatology</title>
</titleInfo>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>49</number>
</detail>
<extent unit="pages"><start>1335</start>
<end>74</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0009"><titleInfo><title>Genetic variation in IL28B and spontaneous clearance of hepatitis C virus</title>
</titleInfo>
<name type="personal"><namePart type="given">DL</namePart>
<namePart type="family">Thomas</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">CL</namePart>
<namePart type="family">Thio</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">MP</namePart>
<namePart type="family">Martin</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ThomasDL, ThioCL, MartinMP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009; 461: 798–801.</note>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>461</number>
</detail>
<extent unit="pages"><start>798</start>
<end>801</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Nature</title>
</titleInfo>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>461</number>
</detail>
<extent unit="pages"><start>798</start>
<end>801</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0010"><titleInfo><title>Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance</title>
</titleInfo>
<name type="personal"><namePart type="given">D</namePart>
<namePart type="family">Ge</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Fellay</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">AJ</namePart>
<namePart type="family">Thompson</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">GeD, FellayJ, ThompsonAJ, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature2009; 461: 399–401.</note>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>461</number>
</detail>
<extent unit="pages"><start>399</start>
<end>401</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Nature</title>
</titleInfo>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>461</number>
</detail>
<extent unit="pages"><start>399</start>
<end>401</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0011"><titleInfo><title>The viral clearance in IFN‐treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies</title>
</titleInfo>
<name type="personal"><namePart type="given">HF</namePart>
<namePart type="family">Lohr</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D</namePart>
<namePart type="family">Schmitz</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Arenz</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">LohrHF, SchmitzD, ArenzM, et al. The viral clearance in IFN‐treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol1999; 31: 407–15.</note>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>31</number>
</detail>
<extent unit="pages"><start>407</start>
<end>15</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Hepatol</title>
</titleInfo>
<part><date>1999</date>
<detail type="volume"><caption>vol.</caption>
<number>31</number>
</detail>
<extent unit="pages"><start>407</start>
<end>15</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0012"><titleInfo><title>Type 1 IFNs enhance the terminal differentiation of dendritic cells</title>
</titleInfo>
<name type="personal"><namePart type="given">T</namePart>
<namePart type="family">Luft</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">KC</namePart>
<namePart type="family">Pang</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">E</namePart>
<namePart type="family">Thomas</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">LuftT, PangKC, ThomasE, et al. Type 1 IFNs enhance the terminal differentiation of dendritic cells. J Immunol1998; 161: 1947–53.</note>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>161</number>
</detail>
<extent unit="pages"><start>1947</start>
<end>53</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Immunol</title>
</titleInfo>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>161</number>
</detail>
<extent unit="pages"><start>1947</start>
<end>53</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0013"><titleInfo><title>Induction of bystander T cell proliferation by viruses and type I interferon in vivo</title>
</titleInfo>
<name type="personal"><namePart type="given">DF</namePart>
<namePart type="family">Tough</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">P</namePart>
<namePart type="family">Borrow</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Sprent</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ToughDF, BorrowP, SprentJ. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science1996; 272: 1947–50.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>272</number>
</detail>
<extent unit="pages"><start>1947</start>
<end>50</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Science</title>
</titleInfo>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>272</number>
</detail>
<extent unit="pages"><start>1947</start>
<end>50</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0014"><titleInfo><title>Type I interferon as a powerful adjuvant for monocyte‐derived dendritic cell development and activity in vitro and in Hu‐ PBL‐SCID mice</title>
</titleInfo>
<name type="personal"><namePart type="given">SM</namePart>
<namePart type="family">Santini</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Lapenta</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Logozzi</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">SantiniSM, LapentaC, LogozziM, et al. Type I interferon as a powerful adjuvant for monocyte‐derived dendritic cell development and activity in vitro and in Hu‐ PBL‐SCID mice. J Exp Med2000; 191: 1777–88.</note>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>191</number>
</detail>
<extent unit="pages"><start>1777</start>
<end>88</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Exp Med</title>
</titleInfo>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>191</number>
</detail>
<extent unit="pages"><start>1777</start>
<end>88</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0015"><titleInfo><title>Protection of hepatocytes from cytotoxic T cell mediated killing by interferon‐alpha</title>
</titleInfo>
<name type="personal"><namePart type="given">CB</namePart>
<namePart type="family">Willberg</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">SM</namePart>
<namePart type="family">Ward</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">RF</namePart>
<namePart type="family">Clayton</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">WillbergCB, WardSM, ClaytonRF, et al. Protection of hepatocytes from cytotoxic T cell mediated killing by interferon‐alpha. PLoS ONE2007; 2: e791.</note>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>e791</start>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>PLoS ONE</title>
</titleInfo>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>2</number>
</detail>
<extent unit="pages"><start>e791</start>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0016"><titleInfo><title>Mechanism of action of interferon and ribavirin in treatment of hepatitis C</title>
</titleInfo>
<name type="personal"><namePart type="given">JJ</namePart>
<namePart type="family">Feld</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JH</namePart>
<namePart type="family">Hoofnagle</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">FeldJJ, HoofnagleJH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature2005; 436: 967–72.</note>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>436</number>
</detail>
<extent unit="pages"><start>967</start>
<end>72</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Nature</title>
</titleInfo>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>436</number>
</detail>
<extent unit="pages"><start>967</start>
<end>72</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0017"><titleInfo><title>Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐alpha therapy</title>
</titleInfo>
<name type="personal"><namePart type="given">AU</namePart>
<namePart type="family">Neumann</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">NP</namePart>
<namePart type="family">Lam</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">H</namePart>
<namePart type="family">Dahari</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">NeumannAU, LamNP, DahariH, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon‐alpha therapy. Science1998; 282: 103–7.</note>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>282</number>
</detail>
<extent unit="pages"><start>103</start>
<end>7</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Science</title>
</titleInfo>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>282</number>
</detail>
<extent unit="pages"><start>103</start>
<end>7</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0018"><titleInfo><title>Peginterferon alone or with ribavirin enhances HCV‐specific CD4 T‐helper 1 responses in patients with chronic hepatitis C</title>
</titleInfo>
<name type="personal"><namePart type="given">SM</namePart>
<namePart type="family">Kamal</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Fehr</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">B</namePart>
<namePart type="family">Roesler</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">T</namePart>
<namePart type="family">Peters</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JW</namePart>
<namePart type="family">Rasenack</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">KamalSM, FehrJ, RoeslerB, PetersT, RasenackJW. Peginterferon alone or with ribavirin enhances HCV‐specific CD4 T‐helper 1 responses in patients with chronic hepatitis C. Gastroenterology2002; 123: 1070–83.</note>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>123</number>
</detail>
<extent unit="pages"><start>1070</start>
<end>83</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Gastroenterology</title>
</titleInfo>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>123</number>
</detail>
<extent unit="pages"><start>1070</start>
<end>83</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0019"><titleInfo><title>Hepatitis C virus‐specific T‐cell reactivity during interferon and ribavirin treatment in chronic hepatitis C</title>
</titleInfo>
<name type="personal"><namePart type="given">ME</namePart>
<namePart type="family">Cramp</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">S</namePart>
<namePart type="family">Rossol</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">S</namePart>
<namePart type="family">Chokshi</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">CrampME, RossolS, ChokshiS, et al. Hepatitis C virus‐specific T‐cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology2000; 118: 346–55.</note>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>118</number>
</detail>
<extent unit="pages"><start>346</start>
<end>55</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Gastroenterology</title>
</titleInfo>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>118</number>
</detail>
<extent unit="pages"><start>346</start>
<end>55</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0020"><titleInfo><title>The dynamics of T‐lymphocyte responses during combination therapy for chronic hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">E</namePart>
<namePart type="family">Barnes</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Harcourt</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D</namePart>
<namePart type="family">Brown</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">BarnesE, HarcourtG, BrownD, et al. The dynamics of T‐lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology2002; 36: 743–54.</note>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>743</start>
<end>54</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Hepatology</title>
</titleInfo>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>743</start>
<end>54</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0021"><titleInfo><title>CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance</title>
</titleInfo>
<name type="personal"><namePart type="given">JH</namePart>
<namePart type="family">Aberle</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Perstinger</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">L</namePart>
<namePart type="family">Weseslindtner</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">AberleJH, PerstingerG, WeseslindtnerL, et al. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance. J Infect Dis2007; 195: 1315–9.</note>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>195</number>
</detail>
<extent unit="pages"><start>1315</start>
<end>9</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Infect Dis</title>
</titleInfo>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>195</number>
</detail>
<extent unit="pages"><start>1315</start>
<end>9</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0022"><titleInfo><title>HCV‐specific T‐cell response in relation to viral kinetics and treatment outcome (DITTO‐HCV project)</title>
</titleInfo>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Pilli</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Zerbini</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Penna</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">PilliM, ZerbiniA, PennaA, et al. HCV‐specific T‐cell response in relation to viral kinetics and treatment outcome (DITTO‐HCV project). Gastroenterology2007; 133: 1132–43.</note>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>133</number>
</detail>
<extent unit="pages"><start>1132</start>
<end>43</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Gastroenterology</title>
</titleInfo>
<part><date>2007</date>
<detail type="volume"><caption>vol.</caption>
<number>133</number>
</detail>
<extent unit="pages"><start>1132</start>
<end>43</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0023"><titleInfo><title>Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long‐lived CD8+ memory T cells</title>
</titleInfo>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Badr</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N</namePart>
<namePart type="family">Bédard</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">MS</namePart>
<namePart type="family">Abdel‐Hakeem</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">BadrG, BédardN, Abdel‐HakeemMS, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long‐lived CD8+ memory T cells. J Virol2008; 82: 10017–31.</note>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>82</number>
</detail>
<extent unit="pages"><start>10017</start>
<end>31</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Virol</title>
</titleInfo>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>82</number>
</detail>
<extent unit="pages"><start>10017</start>
<end>31</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0024"><titleInfo><title>Immunodominant CD4 + T‐cell epitope within nonstructural protein 3 in acute hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">HM</namePart>
<namePart type="family">Diepolder</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JT</namePart>
<namePart type="family">Gerlach</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Zachoval</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">DiepolderHM, GerlachJT, ZachovalR, et al. Immunodominant CD4 + T‐cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol1997; 71: 6011–9.</note>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>71</number>
</detail>
<extent unit="pages"><start>6011</start>
<end>9</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Virol</title>
</titleInfo>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>71</number>
</detail>
<extent unit="pages"><start>6011</start>
<end>9</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0025"><titleInfo><title>Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence</title>
</titleInfo>
<name type="personal"><namePart type="given">B</namePart>
<namePart type="family">Rehermann</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">RehermannB. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest2009; 119: 1745–54.</note>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>119</number>
</detail>
<extent unit="pages"><start>1745</start>
<end>54</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Invest</title>
</titleInfo>
<part><date>2009</date>
<detail type="volume"><caption>vol.</caption>
<number>119</number>
</detail>
<extent unit="pages"><start>1745</start>
<end>54</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0026"><titleInfo><title>National institutes of health consensus development conference statement. Management of Hepatitis C</title>
</titleInfo>
<name type="personal"><namePart type="given">B. Seeff</namePart>
<namePart type="family">Leonard</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">H. Hoofnagle</namePart>
<namePart type="family">Jay</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">LeonardB. Seeff, JayH. Hoofnagle. National institutes of health consensus development conference statement. Management of Hepatitis C. Hepatology2003; 36: s1–2.</note>
<part><date>2003</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>s1</start>
<end>2</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Hepatology</title>
</titleInfo>
<part><date>2003</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>s1</start>
<end>2</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0027"><titleInfo><title>Memory T cells established by seasonal human influenza A infection cross‐react with avian influenza A (H5N1) in healthy individuals</title>
</titleInfo>
<name type="personal"><namePart type="given">LY</namePart>
<namePart type="family">Lee</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">LA</namePart>
<namePart type="family">Ha do</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Simmons</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">LeeLY, Ha doLA, SimmonsC, et al. Memory T cells established by seasonal human influenza A infection cross‐react with avian influenza A (H5N1) in healthy individuals. J Clin Invest2008; 118: 3478–90.</note>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>118</number>
</detail>
<extent unit="pages"><start>3478</start>
<end>90</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Clin Invest</title>
</titleInfo>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>118</number>
</detail>
<extent unit="pages"><start>3478</start>
<end>90</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0028"><titleInfo><title>Identifying ELISPOT and skin test cut‐offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia</title>
</titleInfo>
<name type="personal"><namePart type="given">DJ</namePart>
<namePart type="family">Jeffries</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">PC</namePart>
<namePart type="family">Hill</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Fox</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">JeffriesDJ, HillPC, FoxA, et al. Identifying ELISPOT and skin test cut‐offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia. Int J Tuberc Lung Dis2006; 10: 192–8.</note>
<part><date>2006</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<extent unit="pages"><start>192</start>
<end>8</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Int J Tuberc Lung Dis</title>
</titleInfo>
<part><date>2006</date>
<detail type="volume"><caption>vol.</caption>
<number>10</number>
</detail>
<extent unit="pages"><start>192</start>
<end>8</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0029"><titleInfo><title>Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials</title>
</titleInfo>
<name type="personal"><namePart type="given">JH</namePart>
<namePart type="family">Cox</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Ferrari</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">SA</namePart>
<namePart type="family">Kalams</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="corporate"><namePart>Elispot Collaborative Study Group</namePart>
</name>
<genre>journal-article</genre>
<note type="citation/reference">CoxJH, FerrariG, KalamsSA, et al. Elispot Collaborative Study Group. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses2005; 21: 68–81.</note>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>21</number>
</detail>
<extent unit="pages"><start>68</start>
<end>81</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>AIDS Res Hum Retroviruses</title>
</titleInfo>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>21</number>
</detail>
<extent unit="pages"><start>68</start>
<end>81</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0030"><titleInfo><title>Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV‐1)‐specific T‐cell responses directed against the entire expressed HIV‐1 genome demonstrate broadly directed responses, but no correlation to viral load</title>
</titleInfo>
<name type="personal"><namePart type="given">MM</namePart>
<namePart type="family">Addo</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">XG</namePart>
<namePart type="family">Yu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Rathod</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">AddoMM, YuXG, RathodA, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV‐1)‐specific T‐cell responses directed against the entire expressed HIV‐1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol2003; 77: 2081–92.</note>
<part><date>2003</date>
<detail type="volume"><caption>vol.</caption>
<number>77</number>
</detail>
<extent unit="pages"><start>2081</start>
<end>92</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Virol</title>
</titleInfo>
<part><date>2003</date>
<detail type="volume"><caption>vol.</caption>
<number>77</number>
</detail>
<extent unit="pages"><start>2081</start>
<end>92</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0031"><titleInfo><title>Determinants of viral clearance and persistence during acute hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Thimme</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D</namePart>
<namePart type="family">Oldach</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">KM</namePart>
<namePart type="family">Chang</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ThimmeR, OldachD, ChangKM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med2001; 194: 1395–406.</note>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>194</number>
</detail>
<extent unit="pages"><start>1395</start>
<end>406</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Exp Med</title>
</titleInfo>
<part><date>2001</date>
<detail type="volume"><caption>vol.</caption>
<number>194</number>
</detail>
<extent unit="pages"><start>1395</start>
<end>406</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0032"><titleInfo><title>Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease</title>
</titleInfo>
<name type="personal"><namePart type="given">R</namePart>
<namePart type="family">Thimme</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Bukh</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">HC</namePart>
<namePart type="family">Spangenberg</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ThimmeR, BukhJ, SpangenbergHC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA2002; 99: 15661–8.</note>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>99</number>
</detail>
<extent unit="pages"><start>15661</start>
<end>8</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title>
</titleInfo>
<part><date>2002</date>
<detail type="volume"><caption>vol.</caption>
<number>99</number>
</detail>
<extent unit="pages"><start>15661</start>
<end>8</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0033"><titleInfo><title>Cellular immune selection with hepatitis C virus persistence in humans</title>
</titleInfo>
<name type="personal"><namePart type="given">AL</namePart>
<namePart type="family">Cox</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">T</namePart>
<namePart type="family">Mosbruger</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">Q</namePart>
<namePart type="family">Mao</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">CoxAL, MosbrugerT, MaoQ, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med2005; 201: 1741–52.</note>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>201</number>
</detail>
<extent unit="pages"><start>1741</start>
<end>52</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Exp Med</title>
</titleInfo>
<part><date>2005</date>
<detail type="volume"><caption>vol.</caption>
<number>201</number>
</detail>
<extent unit="pages"><start>1741</start>
<end>52</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0034"><titleInfo><title>Prospective analysis of effector and regulatory CD4 +  T cells in chronic HCV patients undergoing combination antiviral therapy</title>
</titleInfo>
<name type="personal"><namePart type="given">JR</namePart>
<namePart type="family">Burton</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J</namePart>
<namePart type="family">Klarquist</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">K</namePart>
<namePart type="family">Im</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="corporate"><namePart>Virahep‐C Study Group</namePart>
</name>
<genre>journal-article</genre>
<note type="citation/reference">BurtonJR Jr, KlarquistJ, ImK, et al. Virahep‐C Study Group. Prospective analysis of effector and regulatory CD4 +  T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol2008; 49: 329–38.</note>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>49</number>
</detail>
<extent unit="pages"><start>329</start>
<end>38</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Hepatol</title>
</titleInfo>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>49</number>
</detail>
<extent unit="pages"><start>329</start>
<end>38</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0035"><titleInfo><title>T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)‐HIV‐co‐infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Arizcorreta</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Márquez</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">C</namePart>
<namePart type="family">Fernández‐Gutiérrez</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">ArizcorretaA, MárquezM, Fernández‐GutiérrezC, et al. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)‐HIV‐co‐infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol2006; 146: 270–7.</note>
<part><date>2006</date>
<detail type="volume"><caption>vol.</caption>
<number>146</number>
</detail>
<extent unit="pages"><start>270</start>
<end>7</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Clin Exp Immunol</title>
</titleInfo>
<part><date>2006</date>
<detail type="volume"><caption>vol.</caption>
<number>146</number>
</detail>
<extent unit="pages"><start>270</start>
<end>7</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0036"><titleInfo><title>Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus</title>
</titleInfo>
<name type="personal"><namePart type="given">MS</namePart>
<namePart type="family">Abdel‐Hakeem</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">N</namePart>
<namePart type="family">Bédard</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Badr</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">Abdel‐HakeemMS, BédardN, BadrG, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol2010; 84: 10429–35.</note>
<part><date>2010</date>
<detail type="volume"><caption>vol.</caption>
<number>84</number>
</detail>
<extent unit="pages"><start>10429</start>
<end>35</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>J Virol</title>
</titleInfo>
<part><date>2010</date>
<detail type="volume"><caption>vol.</caption>
<number>84</number>
</detail>
<extent unit="pages"><start>10429</start>
<end>35</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0037"><titleInfo><title>Selection of high‐avidity CD8 T cells correlates with control of hepatitis C virus infection</title>
</titleInfo>
<name type="personal"><namePart type="given">B</namePart>
<namePart type="family">Neveu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">E</namePart>
<namePart type="family">Debeaupuis</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">K</namePart>
<namePart type="family">Echasserieau</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">NeveuB, DebeaupuisE, EchasserieauK, et al. Selection of high‐avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology2008; 48: 713–22.</note>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>48</number>
</detail>
<extent unit="pages"><start>713</start>
<end>22</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Hepatology</title>
</titleInfo>
<part><date>2008</date>
<detail type="volume"><caption>vol.</caption>
<number>48</number>
</detail>
<extent unit="pages"><start>713</start>
<end>22</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<relatedItem type="references" displayLabel="liv2652-cit-0038"><titleInfo><title>Cellular immune responses persist and humoral responses decrease two decades after recovery from a single‐source outbreak of hepatitis C</title>
</titleInfo>
<name type="personal"><namePart type="given">A</namePart>
<namePart type="family">Takaki</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Wiese</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">G</namePart>
<namePart type="family">Maertens</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<genre>journal-article</genre>
<note type="citation/reference">TakakiA, WieseM, MaertensG, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single‐source outbreak of hepatitis C. Nat Med2000; 6: 578–82.</note>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>578</start>
<end>82</end>
</extent>
</part>
<relatedItem type="host"><titleInfo><title>Nat Med</title>
</titleInfo>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>6</number>
</detail>
<extent unit="pages"><start>578</start>
<end>82</end>
</extent>
</part>
</relatedItem>
</relatedItem>
<identifier type="istex">1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D</identifier>
<identifier type="ark">ark:/67375/WNG-JJ0J5KLG-M</identifier>
<identifier type="DOI">10.1111/j.1478-3231.2011.02652.x</identifier>
<identifier type="ArticleID">LIV2652</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 2012 John Wiley & Sons A/S© 2011 John Wiley & Sons A/S</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource>
<recordOrigin>Converted from  (version ) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/WNG-JJ0J5KLG-M/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001392 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001392 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:1BF3AB38AA82D7674F6A9A3CDEBEA2248530ED2D
   |texte=   Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri